ERT in medicine stands for enzyme replacement therapy, a treatment that delivers lab-made versions of enzymes to people whose bodies can’t produce them naturally. It’s primarily used for a group of rare genetic conditions called lysosomal storage diseases, where a missing or defective enzyme causes toxic substances to build up inside cells. First approved in 1991 for Gaucher disease, ERT is now available for eight of these conditions in the United States.
How Enzyme Replacement Therapy Works
Inside your cells are tiny compartments called lysosomes that act like recycling centers, breaking down waste materials so the cell can reuse or dispose of them. Each type of waste requires a specific enzyme to break it down. When someone is born without the gene to produce one of these enzymes, waste accumulates in their cells over time, gradually damaging organs and tissues.
ERT works by providing a synthetic copy of the missing enzyme through an IV infusion. These lab-made enzymes are engineered with specific sugar molecules on their surface that act like docking keys. Receptors on the outside of your cells recognize these sugar molecules, pull the enzyme inside, and shuttle it to the lysosomes where it can get to work breaking down the accumulated waste. The bulk of the infused enzyme is taken up by the liver, kidneys, and spleen, which is why ERT tends to be most effective at treating organ-related symptoms.
Conditions Treated With ERT
ERT is approved for several lysosomal storage diseases, including Gaucher disease (the first to receive an approved therapy), Fabry disease, Pompe disease, and several types of mucopolysaccharidosis (MPS). Each of these conditions is individually rare, but collectively they affect roughly 1 in every 8,000 births worldwide. The specific enzyme provided differs for each disease, but the basic principle is the same: replace what the body can’t make on its own.
What Treatment Looks Like
ERT is given as an intravenous infusion, typically every one to two weeks, for the rest of a person’s life. There is no cure with ERT. It manages the disease by continuously supplying the enzyme the body lacks. A standard infusion for Pompe disease, for example, takes roughly four hours, though higher doses can extend that to over six hours. That doesn’t include the time needed for IV setup, vital sign checks, and post-infusion monitoring.
Many patients eventually transition from hospital or clinic infusions to receiving treatment at home, which can significantly reduce the disruption to daily life. Children on long-term home infusions for Pompe disease have been able to attend school and maintain relatively normal routines. The shift to home infusion typically happens after a patient has tolerated several infusions without serious reactions.
Side Effects and Immune Reactions
Because ERT introduces a protein the body has never seen before, the immune system sometimes treats it as a foreign invader. Infusion-related reactions are common, especially in the early months of treatment. Most are mild, involving fever and chills that can be managed by slowing the infusion rate or taking antihistamines beforehand.
A more significant concern is the development of neutralizing antibodies. In Fabry disease, roughly 40% of treated males develop these antibodies, which can bind to the replacement enzyme and reduce its effectiveness. Patients who produce no natural version of the enzyme at all are at the highest risk. Once these antibodies form, they tend to persist. Studies tracking patients over a decade have found that the majority remain antibody-positive, which can blunt the long-term benefit of therapy. Severe, life-threatening infusion reactions have also been reported, though they are uncommon.
The Blood-Brain Barrier Problem
One of the most important limitations of ERT is that the replacement enzymes cannot cross the blood-brain barrier, the tightly sealed network of blood vessels that protects the brain from most large molecules in the bloodstream. This means ERT can effectively treat organ damage in the liver, heart, and kidneys, but it does little for neurological symptoms. In conditions like infantile-onset Pompe disease, some children develop significant brain involvement despite years of successful enzyme therapy for their other symptoms. Next-generation therapies are being developed to try to reach the central nervous system, but standard ERT currently cannot.
Cost of Treatment
ERT is one of the most expensive treatments in medicine. A German study of home-infusion patients found that average annual costs were approximately €369,000 (roughly $400,000) across all lysosomal storage disease types. Pompe disease carried the highest price tag at nearly €484,000 per year, while Fabry disease was the least expensive at around €265,000 annually. Because treatment is lifelong, the cumulative cost over a patient’s lifetime can reach into the millions. This has made access and insurance coverage a persistent challenge, particularly in countries without robust rare-disease funding programs.
How ERT Enzymes Are Made
The replacement enzymes are produced using recombinant DNA technology. Scientists insert the human gene for the missing enzyme into living cells, most commonly Chinese hamster ovary cells or human fibroblast cells, which then act as miniature factories, churning out copies of the protein. The enzymes are harvested, purified, and modified to carry the right sugar molecules on their surface so that human cells will recognize and absorb them. Once infused, these enzymes have a short half-life in the bloodstream because cells pull them in quickly through surface receptors, which is both the mechanism that makes the therapy work and the reason infusions need to be repeated so frequently.